Hormonal
Low-dose melatonin (0.3 mg) administered before sleep does not improve sleep duration, quality, or structure in astronauts during spaceflight.
Low-dose melatonin (0.3 mg) is not a reliable sleep aid for astronauts in space. While it worked in lab settings, it failed to improve sleep in the operational spaceflight environment. Do not rely on it as a primary countermeasure for sleep loss in high-stress, irregular environments.
Administration of melatonin (0.3 mg) on alternate nights did not improve sleep.
Why this rating
Double-blind, placebo-controlled, crossover design, but small sample size (n=5).
Source
Sleep, performance, circadian rhythms, and light-dark cycles during two space shuttle flights
Derk‐Jan Dijk et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 2001
DOI 10.1152/ajpregu.2001.281.5.r1647
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →